Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

The release does not mention cost or whether it’s covered by private insurance or Medicare, and in this case, it’s a pretty big omission. This may be an enormously expensive treatment for patients — and it’s why we have a cost criterion in our reviews. The hopeful psoriasis patient who sees this release without a cost discussion might already have their hand on the phone to call their dermatologist. Here’s a very rough estimate of what that patient might face in terms of cost: Based on a conservative wholesale price of roughly $4,000 per 80 mg injection and following the recommendation (found on the package insert) of two injections every two weeks for 12 weeks, followed by monthly injections, we calculated $48,000 for the first 12 weeks plus $36,000 for the following 9 months or $84,000 total. The release stated that by week 12, “76.4 to 81.8 percent of patients had their psoriasis classified as “clear” or “minimal” compared to 3.2% of patients on the placebo. By the 60th week, 68.7 to 78.3 percent of patients had maintained their improvement.” We also wanted more detail on the measured strength of the response for each patient. For example, what constitutes “minimal”? The release adequately addresses harms and notes that long-term side effects are unknown with this sentence: “Adverse events associated with ixekizumab included slightly higher rates of neutropenia (low white blood cell count), yeast infection and inflammatory bowel disease compared to the placebo. The safety of therapy longer than 60 weeks will need to be monitored in the future.” The release clearly and thoroughly describes the three phase 3 international trials at 21 sites, that they enrolled a large number of patients, and that they were randomized and controlled. There was no disease mongering. The release describes what psoriasis is and its prevalence, and explains that these trials were for moderate to severe psoriasis which covers at least 10 percent of the body. The release is very transparent in stating that the drug manufacturer paid for the research and that the lead researcher is a paid consultant to Eli Lilly. The release did not compare the many different ways that patients treat psoriasis, some with topical agents and some with oral steroids or other medications. The release states that the drug has been approved by the FDA following the completion of the trials. This is a strong indication that the drug is or soon will be available. The release should have noted that the drug is already being marketed under the brand name Taltz. The release makes an understated claim to novelty with this quote from the lead researcher: “Ten years ago, we thought complete clearance of this disease was impossible. It wasn’t something we would even try to do. Now with this drug, we’re obtaining response levels higher than ever seen before.” There was no unjustifiable language in the release.
New drug clears psoriasis in clinical trials

All 46 schools in the district serving Grand Junction and the surrounding area were closed and won’t reopen until after the Thanksgiving break so custodians can disinfect surfaces. Norovirus is a highly contagious bug that causes diarrhea, vomiting and other symptoms, and can spread quickly in public places. It’s most common in winter but can be seen any time of year. The outbreak was first seen last week at a high school before spreading to other schools. Officials in the district, the largest in western Colorado with 22,000 students, believe there is now another related strain of the virus that has affected some students who were previously sick. “We are taking this highly unusual action because this virus is extremely contagious and spreading quickly across our schools,” district nursing coordinator Tanya Martin said. It’s not clear how many students have become sick. Some custodians also became ill, slowing down the cleaning process, but it’s unknown if the suspected viruses were to blame. Nicole Comstock, communicable disease deputy branch chief for the state Department of Public Health and Environment, told The Daily Sentinel that there are about 150 to 200 suspected norovirus outbreaks in the state each year. She said most occur at nursing homes but outbreaks at schools are not uncommon. The U.S. Air Force Academy outside Colorado Springs reported that 400 cadets have been sickened by norovirus since October, but the outbreak hasn’t disrupted classes. The Gazette reported that infected cadets are kept on bed rest for at least three days after their symptoms disappear before they can be cleared to return to class and training.
Suspected norovirus outbreak closes 46 Colorado schools.

"The story provided an estimate for the cost of the treatment as well as the reminder that the costs for the doctor’s visit also needed to be factored in. The story provided some idea of the magnitude of benefit from the use of this drug – significantly more people using this medication were able to abstain from drinking entirely for at least 28 days out of the 98 days of the study. Similarly, there was also a reduction of the average 11  drinks per day to 6 1/2 drinks per day for those using this medication as compared with 7 1/2 for those in the placebo group. The inclusion of the anecdotal report of someone who remained sober years after taking the drug implies a duration of effect well beyond the duration of this study: 3 1/2 months. While there is no formal exaggeration of the effect, a cheery anecdote may falsely raise expectations in the reader. The story did mention some of the unpleasant side effects that people taking the drug experienced; although it did not provide information about how frequently they occurred, it mentioned that 20% of the people dropped out of the study which provides a composite of sorts. The story did a fine job reporting on the results of the study; it is clear from the story that only 15% of the people who took the drug quit drinking during the course of the study but that the difference in the average number of drinks per day though lower in the drug treated group, were really not very different than that of the placebo group. While there is no ""disease mongering"" in the sense of exaggerating the scope of the problem, there is implication in this report that the drug under study is more widely applicable than the study demonstrates. The study author was quoted as saying you ""can come in drinking a bottle of scotch a day and get treatment without detox."" In this study, patients who experienced significant withdrawal symptoms with cessation were excluded, as were those who had multiple unsuccessful attempts in the past to stop drinking in inpatient programs. Experts in the field who were not associated with this study were quoted in the story. In addition, the story clearly indicated that the study was funded by the maker of the drug. Although the story did not name names, it did mention that there were three other medications currently approved for use in the treatment of alcoholism. The story couched one benefit for use of the study drug as something for people who want to see their ""own doctors, rather than enter a rehab clinic to dry out."" This is misleading as it makes it seem as though for the other medications currently approved for the treatment of alcoholism, it is necessary to attend a specialized alcohol treatment program. The story did not mention any 12-step programs that some use for treating alcoholism. The story made clear that the drug Topamax is not FDA approved for the treatment of alcoholism but that physicians are free to prescribe it for such use. The story was clear that this is a new use for a prescription medication currently on the market for other uses. Does not appear to rely on a press release."

Alcoholics see hope in new pill

